Labcorp Holdings Inc
LH265.640USD
+4.170+1.59%
Cierre 11/21, 16:00（ET）Cotizaciones retrasadas 15 min
22.05BCap. mercado
25.78P/E TTM
Más Datos de Labcorp Holdings Inc Compañía
Labcorp Holdings Inc. provides comprehensive laboratory services that help doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. The Company provides insights and accelerates to improve health and improve lives through its unparalleled diagnostics and drug development capabilities. The Company operates through two segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The Diagnostics Laboratories segment includes routine testing and specialty/esoteric testing. Dx operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. The Biopharma Laboratory Services segment consists of early development research laboratories and central laboratory services. The Company is focused on four primary specialty testing areas, such as oncology, women's health, autoimmune disease, and neurology.
Información de Labcorp Holdings Inc
Símbolo de cotizaciónLH
Nombre de la empresaLabcorp Holdings Inc
Fecha de salida a bolsaApr 24, 1991
Director ejecutivoMr. Adam H. Schechter
Número de empleados70000
Tipo de seguridadOrdinary Share
Fin del año fiscalApr 24
Dirección358 S Main St
CiudadBURLINGTON
Bolsa de valoresNYSE Consolidated
PaísUnited States of America
Código postal27215
Teléfono13362291127
Sitio Webhttps://www.labcorp.com/
Símbolo de cotizaciónLH
Fecha de salida a bolsaApr 24, 1991
Director ejecutivoMr. Adam H. Schechter
Ejecutivos de Labcorp Holdings Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Adam H. Schechter
Mr. Adam H. Schechter
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
87.57K
-6.16%
Dr. Brian J. Caveney, M.D., J.D.
Dr. Brian J. Caveney, M.D., J.D.
Executive Vice President, President, Early Development Research Laboratories, Chief Medical and Scientific Officer
Executive Vice President, President, Early Development Research Laboratories, Chief Medical and Scientific Officer
30.07K
-6.24%
Mr. Lance V. Berberian
Mr. Lance V. Berberian
Executive Vice President - Special Advisor, Strategy
Executive Vice President - Special Advisor, Strategy
22.53K
+9.59%
Mr. Peter M. Neupert
Mr. Peter M. Neupert
Independent Director
Independent Director
12.89K
--
Dr. Garheng Kong, M.D., Ph.D.
Dr. Garheng Kong, M.D., Ph.D.
Lead Independent Director
Lead Independent Director
12.84K
--
Ms. Kerrii B. Anderson, CPA
Ms. Kerrii B. Anderson, CPA
Independent Director
Independent Director
8.67K
-31.58%
Ms. Amy B. Summy
Ms. Amy B. Summy
Executive Vice President, Chief Marketing Officer
Executive Vice President, Chief Marketing Officer
5.30K
+16.66%
Mr. Mark S. Schroeder
Mr. Mark S. Schroeder
Executive Vice President and President, Diagnostics Laboratories and Chief Operations Officer
Executive Vice President and President, Diagnostics Laboratories and Chief Operations Officer
4.96K
--
Mr. Akinbolade Oyegunwa
Mr. Akinbolade Oyegunwa
Executive Vice President and Chief Information and Technology Officer
Executive Vice President and Chief Information and Technology Officer
3.73K
+7.59%
Ms. Megan D. Bailey
Ms. Megan D. Bailey
Executive Vice President and President - Central Laboratories and International
Executive Vice President and President - Central Laboratories and International
3.59K
+5.61%
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Adam H. Schechter
Mr. Adam H. Schechter
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
87.57K
-6.16%
Dr. Brian J. Caveney, M.D., J.D.
Dr. Brian J. Caveney, M.D., J.D.
Executive Vice President, President, Early Development Research Laboratories, Chief Medical and Scientific Officer
Executive Vice President, President, Early Development Research Laboratories, Chief Medical and Scientific Officer
30.07K
-6.24%
Mr. Lance V. Berberian
Mr. Lance V. Berberian
Executive Vice President - Special Advisor, Strategy
Executive Vice President - Special Advisor, Strategy
22.53K
+9.59%
Mr. Peter M. Neupert
Mr. Peter M. Neupert
Independent Director
Independent Director
12.89K
--
Dr. Garheng Kong, M.D., Ph.D.
Dr. Garheng Kong, M.D., Ph.D.
Lead Independent Director
Lead Independent Director
12.84K
--
Ms. Kerrii B. Anderson, CPA
Ms. Kerrii B. Anderson, CPA
Independent Director
Independent Director
8.67K
-31.58%
Desglose de ingresos
Divisa: USDActualizado: mié., 12 de mar
Divisa: USDActualizado: mié., 12 de mar
FY2021
FY2020
FY2019
La empresa aún no ha revelado los datos relevantes.
Por regiónUSD
Nombre
Ganancia
Proporción
Northern America
13.09B
81.22%
Europe
2.05B
12.72%
Other Countries
976.40M
6.06%
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.
Estadísticas de accionistas
Actualizado: dom., 16 de nov
Actualizado: dom., 16 de nov
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
11.79%
BlackRock Institutional Trust Company, N.A.
5.30%
State Street Investment Management (US)
4.62%
Victory Capital Management Inc.
3.18%
Geode Capital Management, L.L.C.
2.56%
Otro
72.54%
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
11.79%
BlackRock Institutional Trust Company, N.A.
5.30%
State Street Investment Management (US)
4.62%
Victory Capital Management Inc.
3.18%
Geode Capital Management, L.L.C.
2.56%
Otro
72.54%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
50.29%
Investment Advisor/Hedge Fund
38.90%
Research Firm
2.40%
Pension Fund
1.76%
Hedge Fund
1.60%
Bank and Trust
1.56%
Sovereign Wealth Fund
1.25%
Individual Investor
0.37%
Family Office
0.26%
Otro
1.61%
Participación institucional
Actualizado: mié., 1 de oct
Actualizado: mié., 1 de oct
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q3
1802
83.09M
100.23%
+765.81K
2025Q2
1825
81.46M
98.03%
-5.42M
2025Q1
1872
81.69M
97.58%
-5.17M
2024Q4
1872
81.10M
96.90%
-5.32M
2024Q3
1856
80.09M
95.55%
-6.82M
2024Q2
1876
81.29M
96.43%
-7.49M
2024Q1
1904
82.39M
97.73%
-8.65M
2023Q4
1947
83.11M
99.02%
-9.76M
2023Q3
1930
84.34M
99.29%
-7.18M
2023Q2
1934
84.05M
94.75%
-3.56M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
The Vanguard Group, Inc.
9.84M
11.84%
+155.62K
+1.61%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
4.40M
5.3%
-203.29K
-4.41%
Jun 30, 2025
State Street Investment Management (US)
3.86M
4.65%
+36.00K
+0.94%
Jun 30, 2025
Victory Capital Management Inc.
2.20M
2.64%
+2.14M
+3588.62%
Jun 30, 2025
Geode Capital Management, L.L.C.
2.11M
2.54%
+44.63K
+2.16%
Jun 30, 2025
Wellington Management Company, LLP
1.82M
2.19%
+1.55M
+584.94%
Jun 30, 2025
Allspring Global Investments, LLC
2.00M
2.41%
+43.51K
+2.22%
Jun 30, 2025
Select Equity Group, L.P.
2.13M
2.57%
-87.26K
-3.93%
Jun 30, 2025
Diamond Hill Capital Management Inc.
1.82M
2.19%
-128.08K
-6.56%
Jun 30, 2025
Nordea Funds Oy
1.83M
2.2%
+401.81K
+28.15%
Jun 30, 2025
Ver más
ETFs relacionados
Actualizado: jue., 6 de nov
Actualizado: jue., 6 de nov
Nombre
Proporción
iShares U.S. Healthcare Providers ETF
3.89%
Knowledge Leaders Developed World ETF
3.18%
Thrivent Small-Mid Cap ESG ETF
2.26%
SPDR S&P Health Care Services ETF
2%
Brandes US Value ETF
1.75%
Invesco S&P 500 Equal Weight Health Care ETF
1.73%
Madison Covered Call ETF
1.69%
Nuveen ESG Mid-Cap Value ETF
1.57%
Schwab Ariel Opportunities ETF
1.49%
iShares ESG Aware MSCI USA Value ETF
1.43%
Ver más
iShares U.S. Healthcare Providers ETF
Proporción3.89%
Knowledge Leaders Developed World ETF
Proporción3.18%
Thrivent Small-Mid Cap ESG ETF
Proporción2.26%
SPDR S&P Health Care Services ETF
Proporción2%
Brandes US Value ETF
Proporción1.75%
Invesco S&P 500 Equal Weight Health Care ETF
Proporción1.73%
Madison Covered Call ETF
Proporción1.69%
Nuveen ESG Mid-Cap Value ETF
Proporción1.57%
Schwab Ariel Opportunities ETF
Proporción1.49%
iShares ESG Aware MSCI USA Value ETF
Proporción1.43%
Dividendos
Un total de
692.30M
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Jan 09, 2025
LH.NB Interim Cash Dividend of gross USD 0.72 paid on Mar 12, 2025 going ex on Feb 27, 2025
Feb 27, 2025
Mar 12, 2025
Feb 27, 2025
Oct 10, 2024
LH.NB Final Cash Dividend of gross USD 0.72 paid on Dec 13, 2024 going ex on Nov 26, 2024
Nov 26, 2024
Dec 13, 2024
Nov 26, 2024
Jul 25, 2024
LH.NB Interim Cash Dividend of gross USD 0.72 paid on Sep 13, 2024 going ex on Aug 29, 2024
Aug 29, 2024
Sep 13, 2024
Aug 29, 2024
Apr 11, 2024
LH.NB Interim Cash Dividend of gross USD 0.72 paid on Jun 12, 2024 going ex on May 24, 2024
May 28, 2024
Jun 12, 2024
May 24, 2024
Jan 12, 2024
LH.NB Interim Cash Dividend of gross USD 0.72 paid on Mar 13, 2024 going ex on Feb 26, 2024
Feb 27, 2024
Mar 13, 2024
Feb 26, 2024
Oct 12, 2023
LH.NB Final Cash Dividend of gross USD 0.72 paid on Dec 12, 2023 going ex on Nov 07, 2023
Nov 08, 2023
Dec 12, 2023
Nov 07, 2023
Jul 13, 2023
LH.NB Interim Cash Dividend of gross USD 0.72 paid on Sep 08, 2023 going ex on Aug 07, 2023
Aug 08, 2023
Sep 08, 2023
Aug 07, 2023
Apr 06, 2023
LH.NB Interim Cash Dividend of gross USD 0.72 paid on Jun 08, 2023 going ex on May 17, 2023
May 18, 2023
Jun 08, 2023
May 17, 2023
Jan 12, 2023
LH.NB Interim Cash Dividend of gross USD 0.72 paid on Mar 13, 2023 going ex on Feb 22, 2023
Feb 23, 2023
Mar 13, 2023
Feb 22, 2023
Oct 12, 2022
LH.NB Final Cash Dividend of gross USD 0.72 paid on Dec 09, 2022 going ex on Nov 16, 2022
Nov 17, 2022
Dec 09, 2022
Nov 16, 2022
Ver más
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Labcorp Holdings Inc?
Los cinco principales accionistas de Labcorp Holdings Inc son:
The Vanguard Group, Inc. posee 9.84M acciones, lo que representa el 11.84% del total de acciones.
BlackRock Institutional Trust Company, N.A. posee 4.40M acciones, lo que representa el 5.30% del total de acciones.
State Street Investment Management (US) posee 3.86M acciones, lo que representa el 4.65% del total de acciones.
Victory Capital Management Inc. posee 2.20M acciones, lo que representa el 2.64% del total de acciones.
Geode Capital Management, L.L.C. posee 2.11M acciones, lo que representa el 2.54% del total de acciones.
The Vanguard Group, Inc. posee 9.84M acciones, lo que representa el 11.84% del total de acciones.
BlackRock Institutional Trust Company, N.A. posee 4.40M acciones, lo que representa el 5.30% del total de acciones.
State Street Investment Management (US) posee 3.86M acciones, lo que representa el 4.65% del total de acciones.
Victory Capital Management Inc. posee 2.20M acciones, lo que representa el 2.64% del total de acciones.
Geode Capital Management, L.L.C. posee 2.11M acciones, lo que representa el 2.54% del total de acciones.
¿Cuáles son los tres principales tipos de accionista de Labcorp Holdings Inc?
Los tres principales tipos de accionista de Labcorp Holdings Inc son:
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
¿Cuántas instituciones poseen acciones de Labcorp Holdings Inc (LH)?
A fecha de 2025Q3, 1802 instituciones poseen acciones de Labcorp Holdings Inc, con un valor de mercado combinado de aproximadamente 83.09M, lo que representa el 100.23% del total de acciones. En comparación con el 2025Q2, el accionariado institucional ha aumentado en 2.20%.
¿Cuál es la mayor fuente de ganancias de Labcorp Holdings Inc?
El FY2021, el segmento empresarial -- generó la ganancia más alta para Labcorp Holdings Inc, ascendiendo a -- y representando el --% de la ganancia total.
